Website: missionbio.com   |   LinkedIn: linkedin.com/company/mission-bio

One Cell. The Whole Story.

How Mission Bio’s Tapestri® Platform connects genotype to phenotype at single-cell resolution

At a glance

  • Company: Mission Bio (missionbio.com)
  • Headquarters: South San Francisco, California
  • Focus: Single-cell multiomics for precision medicine
  • Platform: Tapestri®: single-cell DNA, DNA + protein, and targeted DNA + RNA from the same cell
  • Working with PSG on: Fractional Sales Development Rep

Why averages aren’t enough

Cancers, edited cells, and engineered cell therapies are mixtures. Bulk assays average across millions of cells and hide the rare clones that drive relapse, resistance, or safety risk. As Mission Bio puts it, the cells driving risk often aren’t the ones driving the average.

Mission Bio built Tapestri to see every cell.

The Tapestri® Platform

Tapestri uses a unique two-step droplet workflow to capture DNA mutations together with other analytes from the same single cell:

  • Single-cell DNA: resolve clonal architecture and co-occurring mutations
  • DNA + protein: link genotype to cell-surface phenotype
  • Targeted DNA + RNA: the first commercial platform to measure genotype and targeted gene expression in the same cell, launched at ASH 2025
  • Genome integrity and CNV analysis for gene-edited and engineered cells
  • Assay Services: custom panel design and complex data analysis

Where Tapestri makes a difference

  • Hematologic malignancies: clonal architecture, measurable residual disease (MRD), and treatment response. In the multicenter BLAST trial, Tapestri single-cell profiling helped identify AML patients likely to benefit from motixafortide
  • Cell and gene therapy: single-cell vector copy number, surface protein, and vector integrity in CAR-T cells
  • Gene editing: CRISPR edit co-occurrence, zygosity, and functional impact
  • Drug discovery and clinical development: Merck and Incyte have presented data generated with Mission Bio’s Assay Services and Tapestri

In 2026, Mission Bio also partnered with the Human Cell Atlas to expand access to single-cell multiomics for researchers worldwide.